MARKET

OGEN

OGEN

ORAGENICS
AMEX

Real-time Quotes | Nasdaq Last Sale

0.7876
+0.0203
+2.65%
After Hours: 0.7900 +0.0024 +0.30% 19:08 07/07 EDT
OPEN
0.7562
PREV CLOSE
0.7673
HIGH
0.8400
LOW
0.7485
VOLUME
4.93M
TURNOVER
--
52 WEEK HIGH
0.9165
52 WEEK LOW
0.3500
MARKET CAP
43.60M
P/E (TTM)
-2.0847
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average OGEN stock price target is 2.500 with a high estimate of 2.500 and a low estimate of 2.500.

EPS

OGEN News

More
Oragenics, Inc. to Present at the June 2020 Virtual Summer Investor Summit
Oragenics, Inc. to Present at the June 2020 Virtual Summer Investor Summit
Business Wire · 06/04 12:00
30 Stocks Moving in Wednesday's Pre-Market Session
Gainers Nano Dimension Ltd. (NASDAQ: NNDM) shares rose 63.8% to $5.57 in pre-market trading. Nano Dimension shares surged 342% on Tuesday after the company and HENSOLDT achieved a major breakthrough in electronics 3D printing.
Benzinga · 05/20 11:16
OGEN: Acquires Noachis Terra Inc.; Will Develop SARS-CoV-2 Vaccine
Zacks Small Cap Research · 05/08 10:45
Oragenics Announces New Member of the Board of Directors
Business Wire · 05/04 11:15
H.C. Wainwright Downgrades Oragenics to Neutral
H.C. Wainwright downgrades Oragenics (AMEX:OGEN) from Buy to Neutral.
Benzinga · 04/16 11:47
The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-Week Highs April 14)
Benzinga · 04/15 12:03
Oragenics' AG013 flunks mid-stage study; shares down 50% premarket
Seeking Alpha - Article · 04/15 11:43
Oragenics, Inc. Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013 for Oral Mucositis in Chemoradiation Treatment of Head and Neck Cancer
Business Wire · 04/15 11:30

Industry

Biotechnology & Medical Research
+1.75%
Pharmaceuticals & Medical Research
-0.01%

Hot Stocks

Symbol
Price
%Change

About OGEN

Oragenics, Inc. is a healthcare company. The Company is focused on developing treatments for oral mucositis and novel antibiotics against infectious disease. The Company is focused on developing of the TerraCoV2 immunization product candidate. The Company’s product candidate includes, OG716, as an antibiotic, as well as other homolog antibiotic product candidates and AG013 for the treatment of oral mucositis in patients undergoing treatment for cancer. The Company have developed other product such as weight loss candidate, LPT3-04 and SMaRT Replacement Therapy.
More

Webull offers kinds of Oragenics Inc stock information, including AMEX:OGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OGEN stock methods without spending real money on the virtual paper trading platform.